Matthew K. Fust
Mr. Fust joined Ultragenyx as a board member in January 2014. Mr. Fust was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. from January 2009 until its acquisition by Amgen, Inc. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer of Jazz Pharmaceuticals, Inc. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust serves on the Board of Directors of Sunesis Pharmaceuticals, Inc., MacroGenics, Inc., and Atara Biotherapeutics, Inc. Mr. Fust received his B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.